Abstract
With almost 40 million people infected with human immunodeficiency virus (HIV), it is one of the most devastating diseases with no cure in sight. Over the past two decades, significant progress has been made to identify and validate drug targets for HIV. However, most of the 20 FDA approved drugs are targeted to two enzymes; reverse transcriptase and protease. Other drug targets derived from HIV and host factors are being validated, and novel compounds are being developed to overcome drug resistance. Recent data indicate that low and residual virus found in tissues of the lymphoid and central nervous system (CNS) is likely due to insufficient drug levels. Thus, improvement in the delivery of anti-HIV drugs to these tissues with limited drug penetration or accumulation, is equally important to maximally suppress viral replication. Novel lipid associated drugs (i.e. indinavir) targeted to the lymphoid tissue have been shown to overcome limited drug exposure in the lymph nodes and to further reduce residual virus in tissue. This review discusses viral and cellular targets that could interrupt viral replication, as well as novel and proven strategies to enhance the delivery of anti-HIV drugs to the lymphoid, CNS, and cells where low viral replication and limited drug levels exist.
Keywords: HIV, selective delivery, cellular targets, HAART, viral latency
Infectious Disorders - Drug Targets
Title: Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs
Volume: 6 Issue: 2
Author(s): Noha N. Salama, Aaron Endsley and Rodney J.Y Ho
Affiliation:
Keywords: HIV, selective delivery, cellular targets, HAART, viral latency
Abstract: With almost 40 million people infected with human immunodeficiency virus (HIV), it is one of the most devastating diseases with no cure in sight. Over the past two decades, significant progress has been made to identify and validate drug targets for HIV. However, most of the 20 FDA approved drugs are targeted to two enzymes; reverse transcriptase and protease. Other drug targets derived from HIV and host factors are being validated, and novel compounds are being developed to overcome drug resistance. Recent data indicate that low and residual virus found in tissues of the lymphoid and central nervous system (CNS) is likely due to insufficient drug levels. Thus, improvement in the delivery of anti-HIV drugs to these tissues with limited drug penetration or accumulation, is equally important to maximally suppress viral replication. Novel lipid associated drugs (i.e. indinavir) targeted to the lymphoid tissue have been shown to overcome limited drug exposure in the lymph nodes and to further reduce residual virus in tissue. This review discusses viral and cellular targets that could interrupt viral replication, as well as novel and proven strategies to enhance the delivery of anti-HIV drugs to the lymphoid, CNS, and cells where low viral replication and limited drug levels exist.
Export Options
About this article
Cite this article as:
Salama N. Noha, Endsley Aaron and Ho J.Y Rodney, Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112137
DOI https://dx.doi.org/10.2174/187152606784112137 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations
and Management in COVID-19 Pandemic
CNS & Neurological Disorders - Drug Targets Endothelial Function Assessment in Complicated Hypertension
Current Pharmaceutical Design Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Current Alzheimer Research Mitogenomics: Recognizing the Significance of Mitochondrial Genomic Variation for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry EDITORIAL (Thematic Issue: Preeclampsia and Modern Approaches to Diagnosis and Therapy)
Current Women`s Health Reviews Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction
Current Clinical Pharmacology Vaccination of Older Adults with Dementia Against Respiratory Infections
Infectious Disorders - Drug Targets Editorial (New Wave from Immunology, Endocrine & Metabolic Agents in Medicinal Chemistr )
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Hyperglycemia-induced Oxidative Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases
Current Pharmaceutical Design Facial Pain Expression in Dementia: A Review of the Experimental and Clinical Evidence
Current Alzheimer Research The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Loss of Medial Septum Cholinergic Neurons in THY-Tau22 Mouse Model: What Links with tau Pathology?
Current Alzheimer Research New Treatments for COPD in the Elderly
Current Pharmaceutical Design Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews